MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), is pleased to announce the commercial launch of a full-spectrum CBD oral oil in Brazil through its pharmaceutical partner, Alko do Brasil Indústria e Comércio Ltda, “Alko”.

MediPharm manufactures the product at its pharmaceutical facility in Barrie, Ontario, which holds ANVISA Good Manufacturing Practices (“GMP”) certification. Alko do Brasil obtained the Sanitary Authorization based on a comprehensive regulatory dossier submitted to ANVISA, with technical and regulatory support from MediPharm Labs, resulting in authorization of the product for medicinal use in Brazil.

Brazil remains one of the world’s most highly regulated cannabinoid markets, requiring foreign manufacturers to comply with applicable ANVISA regulatory requirements and GMP standards and to provide comprehensive documentation related to product quality, stability, manufacturing, regulatory compliance and post-market obligations.

“This launch represents the continued execution of MediPharm’s international growth strategy and further validates our position as a trusted global supplier of cannabinoid-based products manufactured under pharmaceutical quality standards,” said Greg Hunter, Chief Executive Officer of MediPharm Labs.

“Brazil is one of the fastest-growing medical cannabis markets in the world, but it is also one of the most difficult to access from a regulatory perspective. Successfully supporting an ANVISA Sanitary Authorization demonstrates the strength of our pharmaceutical manufacturing capabilities, regulatory expertise and commitment to quality. We are proud to have worked closely with Alko throughout the authorization process and are pleased that patients across Brazil can now access an ANVISA-authorized Cannabis Product manufactured at our GMP-certified facility.”

Brazil is widely regarded as an attractive long-term medical cannabis market. The market has grown rapidly following implementation of ANVISA’s cannabis framework in 2019 and continues to be driven by increasing medical interest and demand for regulated Cannabis Products. Kaya Mind estimates the potential size of Brazil’s medical cannabis market at approximately C$2.58 billion.¹ Under Brazil’s regulatory framework applicable to ANVISA-authorized Cannabis Products, commercialization is focused on pharmaceutical dosage forms rather than dried Cannabis flower, including products such as oils, oral formulations and other dosage forms that meet applicable ANVISA regulatory requirements.

“Alko has seized the opportunity and sees a bright future for their investment in Brazilian cannabis. From the beginning, our objective has been to expand access in Brazil to quality-controlled Cannabis Products manufactured in accordance with the applicable regulatory requirements. MediPharm’s manufacturing capabilities, ANVISA GMP-certified facility and technical expertise were important throughout the regulatory process. We are pleased to make this ANVISA-authorized Cannabis Product available in Brazil through the legally established prescription and pharmacy dispensing channels,” says Alko’s Co-CEO Juliana Komel

MediPharm believes its pharmaceutical manufacturing platform is well positioned to support growth in Brazil. MediPharm is one of a limited number of international cannabinoid manufacturers with the regulatory infrastructure and pharmaceutical manufacturing capabilities necessary to support commercialization in Brazil.